Alzheimer's Rollercoaster: Azeliragon Misses Endpoints, But Responding Subgroup Identified

US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.